Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $7.51 million. The enterprise value is $4.28 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 2.55 million shares outstanding. The number of shares has increased by 7.70% in one year.
| Current Share Class | 2.55M |
| Shares Outstanding | 2.55M |
| Shares Change (YoY) | +7.70% |
| Shares Change (QoQ) | +0.63% |
| Owned by Insiders (%) | 30.88% |
| Owned by Institutions (%) | 15.18% |
| Float | 1.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.71 |
| Forward PS | n/a |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.83
| Current Ratio | 5.83 |
| Quick Ratio | 5.22 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -30.36% and return on invested capital (ROIC) is -22.52%.
| Return on Equity (ROE) | -30.36% |
| Return on Assets (ROA) | -19.76% |
| Return on Invested Capital (ROIC) | -22.52% |
| Return on Capital Employed (ROCE) | -40.99% |
| Revenue Per Employee | $2.00M |
| Profits Per Employee | -$3.06M |
| Employee Count | 1 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.28% in the last 52 weeks. The beta is 1.96, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | -3.28% |
| 50-Day Moving Average | 2.70 |
| 200-Day Moving Average | 2.89 |
| Relative Strength Index (RSI) | 59.88 |
| Average Volume (20 Days) | 12,687 |
Short Selling Information
The latest short interest is 41,890, so 1.65% of the outstanding shares have been sold short.
| Short Interest | 41,890 |
| Short Previous Month | 70,843 |
| Short % of Shares Out | 1.65% |
| Short % of Float | 2.63% |
| Short Ratio (days to cover) | 1.18 |
Income Statement
In the last 12 months, CYCN had revenue of $2.00 million and -$3.06 million in losses. Loss per share was -$1.21.
| Revenue | 2.00M |
| Gross Profit | 2.00M |
| Operating Income | -3.63M |
| Pretax Income | 3.01M |
| Net Income | -3.06M |
| EBITDA | n/a |
| EBIT | -3.63M |
| Loss Per Share | -$1.21 |
Full Income StatementBalance Sheet
The company has $3.23 million in cash and n/a in debt, giving a net cash position of $3.23 million or $1.27 per share.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | n/a |
| Net Cash | 3.23M |
| Net Cash Per Share | $1.27 |
| Equity (Book Value) | 8.85M |
| Book Value Per Share | 3.48 |
| Working Capital | 3.50M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.33M |
| Capital Expenditures | n/a |
| Free Cash Flow | -4.33M |
| FCF Per Share | -$1.70 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -181.40% and -152.85%.
| Gross Margin | 100.00% |
| Operating Margin | -181.40% |
| Pretax Margin | -152.85% |
| Profit Margin | -152.85% |
| EBITDA Margin | n/a |
| EBIT Margin | -181.40% |
| FCF Margin | n/a |